ReviewInternational journal of molecular sciences2025
Oxidative Stress-Mediated Neuroinflammation in the Pathophysiology of Schizophrenia.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Aging in Schizophrenia: Clinical, Biological, and Psychosocial Perspectives.Geriatrics (Basel, Switzerland) · 2026Review
- A Sesquiterpenoid fromInternational journal of molecular sciences · 2026Article
- Glutathione deficiency in the early postnatal developmental period as a neurodevelopmental animal model of schizophrenia.Pharmacological reports : PR · 2026Review
- Genetic variants in purine metabolism and treatment resistance in schizophrenia: evidence supporting the adenosine hypothesis - a pilot study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a complex neuropsychiatric disorder characterized by a diverse range of symptoms, including positive, negative symptoms such as alogia, anhedonia, avolition, and affective flattening, cognitive symptoms, and emotional symptoms as a separate domain. Emerging evidence suggests that oxidative stress and neuroinflammation play crucial roles in the etiopathogenesis of schizophrenia. The aim of this review is the interplay between oxidative stress-defined as an imbalance between reactive oxygen species (ROS) production and antioxidant defenses-and neuroinflammatory processes within the central nervous system. Studies indicate that elevated levels of oxidative markers and pro-inflammatory cytokines are commonly observed in individuals with schizophrenia, pointing to a potential pathophysiological link. The dysregulation of redox homeostasis may exacerbate neuroinflammatory responses, contributing to neuronal damage and the subsequent manifestation of psychiatric symptoms. Furthermore, genetic and environmental factors may interact with these biological processes, influencing individual susceptibility to schizophrenia. Understanding the mechanisms by which oxidative stress and neuroinflammation contribute to the development and progression of schizophrenia could pave the way for novel therapeutic strategies aimed at mitigating these pathological processes and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.